Humira Biosimilars Market

Table Of Contents

Excel Deliverable

1. Dashboard
A. Overall Summary
B. Approved & Launched Biosimilars
C. Investigational & Research Use Biosimilars
D. Inactive / Terminated / Withdrawn Biosimilars
E. Commercialization Partners
F. Partnerships & Collaborations
G. Individual Biosimilar Details

2. Data Table 1: Summary

3. Data Table 2: Approved and Launched Products

4. Data Table 3: Investigational and Research Use Products

5. Data Table 4: Commercialization Partners

6. Data Table 5: Partnerships

7. Appendix I: Pivot Tables

PowerPoint Deliverable

1. Context

2. Executive Summary

3. Overview of Biosimilars

4. About the Reference Product

5. Contemporary Pipeline Analysis
5.1. Approved / Launched Products
5.2. Investigational and Research Use Products
5.3. Inactive / Terminated / Withdrawn Products
5.4. Commercialization Partners

6. Analysis of Partnerships

7. Company Profiles
7.1. Company A, (California, USA)
7.2. Company B, (Guangzhou, China)
7.3. Company C, (Ahmedabad, India)
7.4. Company D, (Incheon, South Korea)
7.5. Company E, (Tehran, Iran)
7.6. Company F, (Pune, India)
7.7. Company G, (Hessen, Germany)
7.8. Company H, (Tokyo, Japan)
7.9. Company I, (Hyderabad, India)
7.10. Company J, (Suzhou, China)
7.11. Company K, (Seoul, South Korea)
7.12. Company L, (New York, USA)
7.13. Company M, (Navi Mumbai, India)
7.14. Company N, (Incheon, South Korea)
7.15. Company O, (Holzkirchen, Germany)
7.16. Company P, (Shanghai, China)
7.17. Company Q, (Ahmedabad, India)

8. Appendices

Source 1: news.abbvie.com/news/abbvie-reports-full-year-and-fourth-quarter-2018-financial-results.htm
Source 2: www.pharmaceutical-technology.com/comment/abbvies-successful-hard-ball-with-humira/#:~:text=While%20Humira's%20primary%20patent%20was,or%20pursue%20their%20own%20settlements.